BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles

Aug 14, 2017

FRANKLIN LAKES, N.J., August 14, 2017 – BD (Becton, Dickinson and Company), a leading global medical technology company, has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the BD BACTEC™ Standard Aerobic and Standard Anaerobic blood culture bottles in plastic. This marks further expansion of the blood culture bottles available in plastic across BD’s industry-leading BD BACTEC™ platform.

The new BD BACTEC™ Standard Aerobic and Standard Anaerobic plastic blood culture bottles are designed for customer convenience for the qualitative culture and recovery of aerobic organisms (bacteria & yeast) and anaerobic microorganisms, respectively, from adult blood culture specimens. This latest addition to BD’s full spectrum of sepsis and health care associated infection solutions represents BD’s continued commitment to meeting customer needs and enhancing laboratory efficiencies. The BD BACTEC™ plastic bottle offerings are smaller and lighter, allowing for easy and safe handling during collection, transport and disposal.

“We are very pleased to announce the expansion of our BD BACTEC™ blood culture plastic bottle offering,” said Steve Conly, Vice President of Microbiology Diagnostics Systems for BD Life Sciences. “With more than 31.5 million cases of sepsis diagnosed and 5.3 million deaths reported each year worldwide1, sepsis continues to place a tremendous health and financial burden on our global health care community. As a global leader in blood culture, expanding our BD BACTEC™ blood culture plastic bottle line demonstrates BD’s continued commitment to the fight against Sepsis.”

The BD BACTEC™ blood culture platform, which includes the BD BACTEC™ automated blood culture instrument, resin and lytic media blood culture bottles, has been shown to improve time to detection and recovery of microorganisms, facilitating changes in antibiotic treatment and antibiotic stewardship.2 For more information, please visit: www.bd.com/ds/ or contact your BD Diagnostics account representative.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com

For more information on BD, please visit bd.com.

Gwen Gordon

858 812 3724
Email Gwen

Back to News Releases



References
  1. American Journal of Respiratory and Critical Care Medicine, Volume 193, Number 3, February 1, 2016
  2. Zadroga, R; Williams, DN: Hansen, GT “Selection of blood culture media matters- BACTEC use in the critically ill facilitates earlier organism detection and antibiotic decision making” WFSICCM Congress Durban 2013

This site uses cookies. If you click accept cookies then all cookies will be written. Please review our cookies policy and configure your cookies for your experience.